CANCER SURVIVORSHIP AND EXERCISE ONCOLOGY
Professor Sandra Hayes, Director of Research
Cancer Council Queensland (CCQ), Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | April 2025
Professor Sandra Hayes is the Director of Research at Cancer Council Queensland (CCQ), where she leads a comprehensive cancer research program encompassing cancer epidemiology, prevention, detection, treatment, and survivorship.
With a BAppSci (Hons) and a PhD in exercise oncology, Professor Hayes’s expertise lies in quantifying the impact of cancer diagnosis and treatment on physical and psychosocial wellbeing, quality of life, and survival. She also evaluates innovative supportive care strategies, particularly exercise, to improve post-cancer lives.
Professor Hayes has authored 170 peer-reviewed publications, been a Chief Investigator on grants totalling more than AUD$20M, leading world-renowned randomised trials and longitudinal oncology cohort studies involving over 9000 participants across more than 10 cancer sites. Recognised internationally as an expert in exercise oncology, Professor Hayes has held executive positions on national and international committees, including the Clinical Oncology Society of Australia and the International Society of Lymphology.
Her research has been funded by several organisations over the past 25 years, including government funding support through National Health and Medical Research Council grants and more recently the Medical Research Future Fund. Professor Hayes has also been supported from funding from organisations such as the National Breast Cancer Foundation and Cancer Council Queensland, as well as international funding from the World Cancer Research Fund.
Her professional activities include peer review for top oncology and exercise science journals and advisory roles for various cancer and exercise organisations. Her research impact includes leading national and international position statements on exercise for cancer patients, co-developing the Clinical Oncology Society of Australia’s physical activity guidelines, and creating resources for the International Exercise is Medicine® campaign.
She has also developed the YWCA Encore breast cancer rehabilitation program and lymphoedema diagnostic criteria used globally.
Source: Supplied
https://orcid.org/0000-0002-7005-5184
-
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
